Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized molecular glue degraders comprising a cereblon (CRBN) binding moiety acting as protein degradation inducers reported to be useful for the treatment of anemia, cancer, diabetes, infections, transplant rejection, inflammation, autoimmune and sarcoidosis, among others.
Zhuhai Yufan Biotechnologies Co. Ltd. has identified molecular glue degraders comprising an E3 ubiquitin protein ligase-binding agent covalently bound to a DNA-binding protein Ikaros (IKZF1)-targeting moiety acting as IKZF1 degradation inducers potentially useful for the treatment of cancer, autoimmune disease, neurodegeneration and inflammatory disorders.
Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another. Kymera and Gilead Sciences Inc. will collaborate on a molecular glue degrader program that targets cyclin-dependent kinase 2 in solid tumors, including breast cancer.
Monte Rosa Therapeutics Inc. has gained IND clearance from the FDA for MRT-8102, a NEK7-directed molecular glue degrader being developed to treat inflammatory conditions linked to NLRP3, IL-1β and IL-6 dysregulation.
Bristol Myers Squibb Co. has identified molecular glue degraders comprising cereblon ligands and a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety acting as GSPT1 degradation inducers reported to be useful for the treatment of cancer.
Hangzhou Polymed Biopharmaceuticals Inc. has divulged molecular glue degraders comprising cereblon (CRBN) binding agents covalently bound to a zinc finger protein Helios (IKZF2)-targeting moiety acting as IKZF2 degradation and IKZF2/CRBN interaction inducers.
Shanghai Helioson Pharmaceutical Co. Ltd. has synthesized molecular glue degraders comprising an E3 ubiquitin ligase coupled to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety acting as GSPT1 degradation inducers reported to be useful for the treatment of cancer.
A Bristol Myers Squibb Co. patent detailed new substituted phenyl oxooxazolyl piperidine dione molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1), zinc finger protein Helios (IKZF2), Aiolos (IKZF3) and Eos (IKZF4) degradation inducers potentially useful for the treatment of cancer.
Proxygen GmbH has divulged molecular glue degraders comprising a cullin-ring E3 ligase (CRL)-binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be useful for the treatment of cancer.
